Sasha Campbell

Jan 3, 2019

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems.  Johnson & Johnson Innovation LLC facilitated the transaction.

Nov 28, 2018

Partner Profile: BRI Taps NC State Talent and Technology

Partnerships with NC State University’s research and academic programs have played a role in BioResource International’s success from the company’s start nearly 20 years ago – and they will in the future, as well.

Aug 16, 2018

Meet the 2019 Chancellor’s Innovation Fund Recipients

Groundbreaking research happens every day at NC State, and a growing number of important technologies are making the leap from lab to marketplace. It’s no surprise that adequate funding is crucial to this transition.

Aug 6, 2018

NCSU, UNC researchers develop drug-delivery system for rapid heart attack response

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug-delivery system that allows rapid response to heart attacks without surgical intervention.…

Jul 19, 2018

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and…

Jun 14, 2018

Semiconductor firm HexaTech raises $2.7M in equity, wants $800,000 more

HexaTech, a spinout based on research into aluminum nitrides at North Carolina State University, is raising a new round of equity. According to a securities filing Thursday, the company has…

May 23, 2018

NC State Pharma startup Emergo Therapeutics lands $12M from REX Health Ventures, Triangle backers

An all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital. Leading the round, which was announced Wednesday, is REX Health Ventures. Other…

Apr 12, 2018

76 investors back NC State biopolymer startup Tethis in $3.6M funding

Tethis IP Holding Co., a biopolymer manufacturer, has raised $3.6 million according to a filing with the Securities and Exchange Commission. The Raleigh-based company raised the money in the form of…

Mar 28, 2018

NC State Office of Technology Commercialization and New Ventures partners with RIoT to Increase Entrepreneurship Resources

As an aspiring entrepreneur or young start-up, it can be hard to navigate the ever-evolving technology commercialization process and get your service or product out into the market. NC State…

Mar 13, 2018

NC State Startup’s Cloud-Computing Tool Moves from the Lab to the Marketplace

It’s always exciting for scientists to see their ideas come to fruition in the lab. For NC State computer science researcher Helen Gu, that idea was a new approach to identifying…